4.8 Article

Impact of pre-existing dengue immunity on human antibody and memory B cell responses to Zika

Journal

NATURE COMMUNICATIONS
Volume 10, Issue -, Pages -

Publisher

NATURE PORTFOLIO
DOI: 10.1038/s41467-019-08845-3

Keywords

-

Funding

  1. National Institute of Allergy and Infectious Diseases (NIH) [P01AI106695, U19AI118610, R01AI099631]
  2. Pediatric Dengue Vaccine Initiative grant VE-1 from the Bill and Melinda Gates Foundation
  3. FIRST grant from the Bill and Melinda Gates Foundation
  4. Instituto Carlos Slim de la Salud

Ask authors/readers for more resources

Little is known about enduring memory B cell (MBC) responses to Zika virus (ZIKV) and their relationship with circulating antibodies. Here we comprehensively assess MBC frequency and specificity alongside serum binding and neutralizing antibody responses to ZIKV similar to 2 weeks and similar to 8 months postinfection in 31 pediatric subjects with 0, 1 or >1 prior infections with the related dengue virus (DENV). ZIKV infection elicits a robust type-specific MBC response, and the majority of late convalescent anti-ZIKV serum neutralizing activity is attributable to ZIKV-specific antibodies. The number of prior DENV infections does not influence type-specific or cross-reactive MBC responses, although ZIKV has the highest cross-reactivity with DENV3. DENV cross-reactive MBCs expanded by ZIKV infection decline in number and proportion by late convalescence. Finally, ZIKV induces greater cross-reactivity in the MBC pool than in serum antibodies. Our data suggest immunity to DENV only modestly shapes breadth and magnitude of enduring ZIKV antibody responses.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available